オーラプテン (Synonyms: Auraptene)

Name: Auraptene
Brand: MedChemExpress
SKU: HY-N2388
Rating: 4.5 (0 reviews)

製品番号: HY-N2388 純度: 99.97%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Auraptene is an orally active geranyloxycoumarin that can be isolated from plants in the Brassicaceae family, antibacterial, anti-pathogen, antioxidant, anti-tumor, and neuroprotective effects. Auraptene plays an important role in the treatment of various chronic diseases such as hypertension and cystic fibrosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

オーラプテン 構造式

CAS 番号 : 495-02-3

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 49	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 49	在庫あり	Estimated Time of Arrival: December 31
Solid
1 mg	$21	在庫あり	Estimated Time of Arrival: December 31
5 mg	$45	在庫あり	Estimated Time of Arrival: December 31
10 mg	$50	在庫あり	Estimated Time of Arrival: December 31
50 mg	$95	在庫あり	Estimated Time of Arrival: December 31
100 mg	$170	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Other Forms of Auraptene:

Auraptene (Standard) お問い合わせ

MMP アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

PPAR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PPARα PPARβ/δ PPARγ PPAR PPARδ

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[1]

MMP-2

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	47 3 Compound: 8, Auraptene	Anticorpulence activity against mouse 3T3L1 cells assessed as inhibition of lipid droplet accumulation Anticorpulence activity against mouse 3T3L1 cells assessed as inhibition of lipid droplet accumulation	[PMID: 19054677]
A549	IC₅₀	82 3 Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
3T3-L1	IC₅₀	47 3 Compound: 8, Auraptene	Anticorpulence activity against mouse 3T3L1 cells assessed as inhibition of lipid droplet accumulation Anticorpulence activity against mouse 3T3L1 cells assessed as inhibition of lipid droplet accumulation	[PMID: 19054677]
BT-549	IC₅₀	24 3 Compound: 7	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
A549	IC₅₀	82 3 Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
A549	IC₅₀	82 3 Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
HT-29	IC₅₀	> 500 3 Compound: 8, Auraptene	Anticancer activity against human HT-29 cells after 72 hrs by MTT assay Anticancer activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 19054677]
BT-549	IC₅₀	24 3 Compound: 7	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
HT-29	IC₅₀	>500 3 Compound: 8, Auraptene	Anticancer activity against human HT-29 cells after 72 hrs by MTT assay Anticancer activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 19054677]
Jurkat	IC₅₀	55.36 6 Compound: Auraptene	Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay	[PMID: 21546250]
BT-549	IC₅₀	24 3 Compound: 7	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
LoVo	IC₅₀	66 3 Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
Jurkat	IC₅₀	55.36 6 Compound: Auraptene	Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay	[PMID: 21546250]
MDA-MB-231	IC₅₀	80 3 Compound: 7	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
LoVo	IC₅₀	66 3 Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
HT-29	IC₅₀	> 500 3 Compound: 8, Auraptene	Anticancer activity against human HT-29 cells after 72 hrs by MTT assay Anticancer activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 19054677]
MDCK	CC₅₀	7 3 Compound: 13a	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28501512]
Jurkat	IC₅₀	55.36 6 Compound: Auraptene	Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay	[PMID: 21546250]
MDA-MB-231	IC₅₀	80 3 Compound: 7	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
PC-3	IC₅₀	65 3 Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
MDCK	CC₅₀	7 3 Compound: 13a	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28501512]
LoVo	IC₅₀	66 3 Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-MEL-28	IC₅₀	87 3 Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
PC-3	IC₅₀	65 3 Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
T47D	IC₅₀	10.2 3 Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
SK-MEL-28	IC₅₀	87 3 Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
T47D	IC₅₀	18.8 3 Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
T47D	IC₅₀	10.2 3 Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
U-373MG ATCC	IC₅₀	82 3 Compound: 1	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
MDA-MB-231	IC₅₀	80 3 Compound: 7	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
T47D	IC₅₀	18.8 3 Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
U-373MG ATCC	IC₅₀	82 3 Compound: 1	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
MDCK	CC₅₀	7 3 Compound: 13a	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28501512]
PC-3	IC₅₀	65 3 Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-MEL-28	IC₅₀	87 3 Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
T47D	IC₅₀	10.2 3 Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1% O2-induced HIF1 activation incubated for 30 mins prior to 1% O2-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
T47D	IC₅₀	18.8 3 Compound: 8, AUR	Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay Inhibition of mitochondrial ETC complex 1 in human T47D cells assessed as inhibition of 1,10-phenanthroline-induced HIF1 activation incubated for 30 mins prior to 1,10-phenanthroline-challenge measured after 16 hrs by luciferase reporter assay	[PMID: 23434131]
U-373MG ATCC	IC₅₀	82 3 Compound: 1	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]

体外実験

Auraptene (0-20 μM, 2 h) reduces the secretion of inflammatory mediators stimulated by lipopolysaccharides in oral epithelial cells and promotes wound healing by promoting cell migration^[1].
Auraptene (10 μM, 24 h) inhibits the cell cycle progression of human breast cancer cell line MCF-7 by reducing the expression of cyclin D1 protein and inhibiting IGF-1^[2].
Auraptene (10 μM, 4 days) exhibits antiviral activity against human coronavirus OC43 in MRC-5 cells^[6].
Auraptene (25-400 μM) protects red blood cells from free radical induced damage by preventing the consumption of intracellular antioxidant GSH and inhibiting protein peroxidation^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1].

Cell Line:	Oral epithelial cell line GMSM-K
Concentration:	0-20 μM
Incubation Time:	2 h
Result:	Didn't affect the survival rate of epithelial cells.

Real Time qPCR^[2].

Cell Line:	MCF-7 cell
Concentration:	10 μM
Incubation Time:	24 h
Result:	Upregulated gene expression levels of CDKN2B (Cyclin dependent kinase inhibitor 2B), DDIT3 (DNA damage inducible transcript 3), and JUN (JUN oncogene).

Real Time qPCR^[6].

Cell Line:	HCoV-OC43-infected human lung fibroblast MRC-5 cells
Concentration:	10 μM
Incubation Time:	4 days
Result:	Decreased viral RNA levels in HCoV-OC43-infected cells.

体内実験

Auraptene (200, 500 ppm, mixed in the diet, p.o.) delays the tumor progression of breast cancer rats by inhibiting cyclin D1 protein^[3].
Auraptene (100, 500 ppm, mixed in the diet, p.o.) alleviates gastritis by reducing Helicobacter pylori colonization and pro-inflammatory mediator production in C57BL/6 mice^[4].
Auraptene (5, 50 mg/kg, 6 weeks, p.o.) prevents heart failure caused by myocardial infarction by activating peroxisome proliferator activated receptor alpha (PPAR alpha) in rats ^[5].
Auraptene (2, 4, 8, 16 mg/kg, 5 weeks, p.o.) exhibits anti hypertensive effects in hypertensive rats by reducing mean systolic blood pressure^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mammary carcinogenesis model in female Sprague Dawley rats^[3].
Dosage:	200, 500 ppm
Administration:	Oral gavage (p.o.); mixed in the diet
Result:	Delayed median time to tumor by 39 days and reduced Insulin like Growth Factor-1 (IGF-1, 10 ng/mL)-induced cyclin D1 expression by 40% in MCF-7 cells.

Animal Model:	Female C57BL/6 mice^[4].
Dosage:	100, 500 ppm
Administration:	Oral gavage (p.o.); mixed in the diet
Result:	Inhibited H. pylori–induced expression and/or production of CD74, macrophage migration inhibitory factor, interleukin-1b, and tumor necrosis factor-a in gastric mucosa, together with serum macrophage inhibitory protein-2.

Animal Model:	Sprague–Dawley rats with moderate myocardial infarction^[5].
Dosage:	5, 50 mg/kg
Administration:	Oral gavage (p.o.); 6 weeks
Result:	Suppresses PE-induced hypertrophic responses in cardiomyocytes. Prevented the development of cardiac hypertrophy and fibrosis in rats with myocardial infarction.

Animal Model:	Desoxycorticosterone acetate (DOCA) salt induced hypertensive rats^[8].
Dosage:	2, 4, 8, 16 mg/kg
Administration:	Oral gavage (p.o.); 5 weeks
Result:	Reduced the mean systolic blood pressure (MSBP) in DOCA salt treated rats.

分子量

298.38

分子式

C₁₉H₂₂O₃

CAS 番号

495-02-3

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C1C=CC2=CC=C(OC/C=C(C)/CC/C=C(C)/C)C=C2O1

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (167.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3514 mL	16.7572 mL	33.5143 mL
5 mM	0.6703 mL	3.3514 mL	6.7029 mL
10 mM	0.3351 mL	1.6757 mL	3.3514 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.97%

Select Batch:

データシート (277 KB) SDS (393 KB)

COA (242 KB) HNMR (194 KB) RP-HPLC (146 KB)

取扱説明書 (2659 KB)

参考文献

[1]. La VD, et al. Anti-inflammatory and wound healing potential of citrus auraptene. J Med Food. 2013 Oct;16(10):961-4. [Content Brief]

[2]. Krishnan P, et al. Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7. Int J Breast Cancer. 2012;2012:502092. [Content Brief]

[3]. Krishnan P, et al. Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats. BMC Cancer. 2009 Jul 29;9:259. [Content Brief]

[4]. Sekiguchi H, et al. Auraptene attenuates gastritis via reduction of Helicobacter pylori colonization and pro-inflammatory mediator production in C57BL/6 mice. J Med Food. 2012 Jul;15(7):658-63. [Content Brief]

[5]. Sunagawa Y, et al. Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats. Phytomedicine. 2022 Dec;107:154457. [Content Brief]

[6]. Min JS, et al. Auraptene Has Antiviral Activity against Human Coronavirus OC43 in MRC-5 Cells. Nutrients. 2023 Jun 29;15(13):2960. [Content Brief]

[7]. Jamialahmadi K, et al. Protective Effects of Auraptene against Free Radical-Induced Erythrocytes Damage. J Pharmacopuncture. 2022 Dec 31;25(4):344-353. [Content Brief]

[8]. Razavi BM, et al. Antihypertensive effect of auraptene, a monoterpene coumarin from the genus Citrus, upon chronic administration. Iran J Basic Med Sci. 2015 Feb;18(2):153-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3514 mL	16.7572 mL	33.5143 mL	83.7858 mL
	5 mM	0.6703 mL	3.3514 mL	6.7029 mL	16.7572 mL
	10 mM	0.3351 mL	1.6757 mL	3.3514 mL	8.3786 mL
	15 mM	0.2234 mL	1.1171 mL	2.2343 mL	5.5857 mL
	20 mM	0.1676 mL	0.8379 mL	1.6757 mL	4.1893 mL
	25 mM	0.1341 mL	0.6703 mL	1.3406 mL	3.3514 mL
	30 mM	0.1117 mL	0.5586 mL	1.1171 mL	2.7929 mL
	40 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0946 mL
	50 mM	0.0670 mL	0.3351 mL	0.6703 mL	1.6757 mL
	60 mM	0.0559 mL	0.2793 mL	0.5586 mL	1.3964 mL
	80 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	100 mM	0.0335 mL	0.1676 mL	0.3351 mL	0.8379 mL

Auraptene Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Auraptene495-02-3MMPPPARBacterialMatrix metalloproteinasesPeroxisome proliferator-activated receptorsantioxidantneuroprotectionMCF-7hypertensive ratsInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

オーラプテン (Synonyms: Auraptene)

カスタマーレビュー

Other Forms of Auraptene:

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

MMP アイソフォーム固有の製品をすべて表示:

PPAR アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Auraptene Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

オーラプテン (Synonyms: Auraptene)

カスタマーレビュー

Other Forms of Auraptene:

オーラプテン 関連抗体

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

MMP アイソフォーム固有の製品をすべて表示:

PPAR アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

オーラプテン 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Auraptene Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

オーラプテン関連抗体

オーラプテン関連抗体